Forte Biosciences, Inc. FBRX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
29/100
Developing

About Forte Biosciences, Inc.

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas. Full FBRX analysis →

Competitive advantage assessment

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.14), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.00), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—

Where FBRX ranks in Biotechnology

Forte Biosciences, Inc. ranks #526 of 713 scored companies in Biotechnology by moat score — the top 74%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near FBRX in Biotechnology
# Company Moat score Rating
522 AC Immune SA ACIU 29/100 Developing
523 Theriva Biologics, Inc. TOVX 29/100 Developing
524 Akari Therapeutics Plc AKTX 29/100 Developing
525 Moleculin Biotech, Inc. MBRX 29/100 Developing
526 Forte Biosciences, Inc. FBRX 29/100 Developing
527 Pluri Inc. PLUR 28/100 Developing
528 Alumis Inc. ALMS 28/100 Developing
529 Aptose Biosciences, Inc. APTO 28/100 Developing
530 Entera Bio Ltd. ENTX 28/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How FBRX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 30 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 26 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding FBRX's moat

What is Forte Biosciences, Inc.'s moat score?

Forte Biosciences, Inc. (FBRX) scores 28 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #526 of 713 scored companies in Biotechnology, the top 74%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (30/100) and its weakest is Resilience (26/100).

How does Forte Biosciences, Inc. compare with other Biotechnology companies?

Forte Biosciences, Inc. ranks #526 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Moleculin Biotech, Inc. (MBRX) at 29 just above it and Pluri Inc. (PLUR) at 28 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Forte Biosciences, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Forte Biosciences, Inc.?

The Corporate Default template measures 6 defenses, and FBRX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (30), Resilience (26), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000